title: Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study.
abstract: BACKGROUND
  The optimal duration of thromboprophylaxis after major orthopedic surgery is controversial. Although oral anticoagulants are still widely used for the prevention of venous thromboembolism after hip replacement, to our knowledge no study has assessed the benefit of prolonging anticoagulation beyond the hospital stay.
  
  
  METHODS
  Consecutive patients who had received warfarin sodium prophylaxis after total hip arthroplasty were randomized to stop taking the drug at the time of hospital discharge or to continue taking it for 4 more weeks. The rate of symptomatic and asymptomatic venous thromboembolic events (as shown by compression ultrasonography of the proximal-vein system) occurring during the study period was compared between the 2 groups. The study was prematurely terminated after the inclusion of the first 360 patients because a statistically significant and clinically relevant superiority of extended over short-term thromboprophylaxis was observed.
  
  
  RESULTS
  Objectively confirmed venous thromboembolic complications were recorded in 10 patients: 9 (5.1%) in the group of 176 control patients, and 1 (0.5%) in the group of 184 patients who continued the warfarin treatment. The absolute difference in the incidence of events was 4.57% (95% confidence interval [CI], 1.15-7.99). The relative risk of venous thromboembolism developing in control patients compared with patients assigned to extended thromboprophylaxis was 9.4 (95% CI, 1.2-73.5). The number needed to treat was 22. Major bleeding developed in 1 patient who was randomized to the extended prophylaxis group (0.5%; 95% CI, 0.02-3.0) compared with none in the control group.
  
  
  CONCLUSIONS
  Extending prophylaxis with warfarin for a few more weeks beyond the hospital stay has the potential to considerably improve the outcome of patients who undergo hip arthroplasty.
authors.affiliation: Department of Medical and Surgical Sciences, Second Chair of Internal Medicine, University Hospital of Padua, Via Ospedale Civile 105, 35128 Padua, Italy. paoprand@tin.it
authors.forename: Paolo
authors.initials: P
authors.lastname: Prandoni
authors.forename: Olinto
authors.initials: O
authors.lastname: Bruchi
authors.forename: Paola
authors.initials: P
authors.lastname: Sabbion
authors.forename: Cinzia
authors.initials: C
authors.lastname: Tanduo
authors.forename: Alberta
authors.initials: A
authors.lastname: Scudeller
authors.forename: Corrado
authors.initials: C
authors.lastname: Sardella
authors.forename: Gabriella
authors.initials: G
authors.lastname: Errigo
authors.forename: Francesco
authors.initials: F
authors.lastname: Pietrobelli
authors.forename: Gianni
authors.initials: G
authors.lastname: Maso
authors.forename: Antonio
authors.initials: A
authors.lastname: Girolami
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use*; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D019934:International Normalized Ratio; D007558:Italy; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000209:etiology; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000517:prevention & control*; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D014859:Warfarin